Advertisement
Screener

GENELUX CORPORATION (GNLX) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

GENELUX CORPORATION Comprehensive Income

GENELUX CORPORATION (GNLX) reported Comprehensive Income of -$9.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Income Statement

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13

  • GENELUX CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$9.47M.
  • GENELUX CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$8.94M.
  • GENELUX CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$9.25M.
  • GENELUX CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$7.95M.
  • GENELUX CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$32.20M.
  • GENELUX CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$29.82M.
  • GENELUX CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$28.29M.
  • GENELUX CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$5.21M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2026-06-30-$9.47M
10-Q · filed 2026-08-13
-$18.41M
10-Q · filed 2026-08-13
-$27.66M
derived: sum of 3 quarters · filed 2026-08-13
-$35.60M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31-$8.94M
10-Q · filed 2026-05-07
-$18.19M
derived: sum of 2 quarters · filed 2026-05-07
-$26.13M
derived: sum of 3 quarters · filed 2026-05-07
-$33.62M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31-$9.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$17.19M
derived: sum of 2 quarters · filed 2026-03-19
-$24.67M
derived: sum of 3 quarters · filed 2026-08-13
-$32.20M
10-K · filed 2026-03-19
2025-09-30-$7.95M
10-Q · filed 2025-11-05
-$15.43M
derived: sum of 2 quarters · filed 2026-08-13
-$22.95M
10-Q · filed 2025-11-05
-$31.99M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30-$7.48M
10-Q · filed 2026-08-13
-$15.01M
10-Q · filed 2026-08-13
-$24.05M
derived: sum of 3 quarters · filed 2026-08-13
-$30.38M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$7.53M
10-Q · filed 2026-05-07
-$16.56M
derived: sum of 2 quarters · filed 2026-05-07
-$22.89M
derived: sum of 3 quarters · filed 2026-05-07
-$29.48M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$9.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$15.37M
derived: sum of 2 quarters · filed 2026-03-19
-$21.95M
derived: sum of 3 quarters · filed 2026-03-19
-$29.82M
10-K · filed 2026-03-19
2024-09-30-$6.33M
10-Q · filed 2025-11-05
-$12.91M
derived: sum of 2 quarters · filed 2025-11-05
-$20.78M
10-Q · filed 2025-11-05
-$27.54M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30-$6.58M
10-Q · filed 2025-08-07
-$14.45M
10-Q · filed 2025-08-07
-$21.21M
derived: sum of 3 quarters · filed 2025-08-07
-$26.55M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$7.87M
10-Q · filed 2025-05-06
-$14.62M
derived: sum of 2 quarters · filed 2025-05-06
-$19.97M
derived: sum of 3 quarters · filed 2025-05-06
-$25.79M
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31-$6.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28
-$12.10M
derived: sum of 2 quarters · filed 2025-03-28
-$17.92M
derived: sum of 3 quarters · filed 2025-03-28
-$28.29M
10-K · filed 2025-03-28
2023-09-30-$5.34M
10-Q · filed 2024-11-14
-$11.17M
derived: sum of 2 quarters · filed 2024-11-14
-$21.53M
10-Q · filed 2024-11-14
2023-06-30-$5.82M
10-Q · filed 2024-08-14
-$16.18M
10-Q · filed 2024-08-14
2023-03-31-$10.36M
10-Q · filed 2024-05-09
2022-12-31-$5.21M
10-K · filed 2024-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Equillium, Inc. (EQ)United States$0.109B-11.27
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ProMIS Neurosciences Inc. (PMN)$0.102B
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95